| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2012 | EP2408426A2 Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids |
| 01/25/2012 | EP2408424A2 Dry processing of retigabine |
| 01/25/2012 | EP2408423A2 Zoo-technical drug delivery device |
| 01/25/2012 | EP2408320A1 Kit of parts comprising l-glutamine and egcg |
| 01/25/2012 | EP2408318A1 Use of whole grain materials with high resistant starch for satiety, reduction of food intake and weight management |
| 01/25/2012 | EP2408306A1 Substituted nucleoside and nucleotide analogs |
| 01/25/2012 | EP2408304A1 Cgrp receptor antagonists |
| 01/25/2012 | EP2408303A1 Morphinan derivatives with high oral bioavailability |
| 01/25/2012 | EP2408302A1 Ophthalmic formulations of ketotifen and methods of use |
| 01/25/2012 | EP2408300A1 Amino ester derivatives, salts thereof and methods of use |
| 01/25/2012 | EP2408299A1 Fatty acid monoglyceride compositions |
| 01/25/2012 | EP2328890B1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 01/25/2012 | EP2280688B1 Aqueous pharmaceutical formulation |
| 01/25/2012 | EP2235011B1 Substituted pyrrolo[2, 3-b]and pyrazolo[3, 4-b]pyridines for use as adenosine receptor ligands |
| 01/25/2012 | EP2215092B1 Substituted piperidino-dihydrothienopyrimidines |
| 01/25/2012 | EP2197428B1 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof |
| 01/25/2012 | EP2150241B1 Sustained release microtablets comprising tolterodine tartrate |
| 01/25/2012 | EP2134691B1 Quinolinone derivatives as parp and tank inhibitors |
| 01/25/2012 | EP2114924B1 Co-crystals and pharmaceutical compositions comprising the same |
| 01/25/2012 | EP2100877B1 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 01/25/2012 | EP2086938B1 Organic compounds |
| 01/25/2012 | EP2079743B1 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| 01/25/2012 | EP2049513B1 Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 01/25/2012 | EP2034017B1 Gene involved in immortalization of human cancer cell and use thereof |
| 01/25/2012 | EP2029538B1 Benzylpiperazine derivatives as motilin receptor antagonists |
| 01/25/2012 | EP2004177B1 Nitrofuran compounds for the treatment of cancer and angiogenesis |
| 01/25/2012 | EP1988075B1 Pyrrole derivative or salt thereof |
| 01/25/2012 | EP1981851B1 Kinase inhibitors and methods of use thereof |
| 01/25/2012 | EP1968982B1 Thieno (3,2-c) pyridine compounds |
| 01/25/2012 | EP1967188B1 Pharmaceutical preparation of an aqueous solution containing platinum complex |
| 01/25/2012 | EP1917259B1 Pyrazine kinase inhibitors |
| 01/25/2012 | EP1901729B1 Pharmaceutical formulations of hdac inhibitors |
| 01/25/2012 | EP1879591B1 Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
| 01/25/2012 | EP1804804B1 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS |
| 01/25/2012 | EP1797047B1 Hiv inhibiting 5-substituted pyrimidines |
| 01/25/2012 | EP1784183B1 Processes for the preparation of isothiazole derivatives |
| 01/25/2012 | EP1781639B1 Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 01/25/2012 | EP1781631B1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 01/25/2012 | EP1773314B1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 01/25/2012 | EP1765778B1 N-sulfonylcarboximidamide apoptosis promoters |
| 01/25/2012 | EP1725245B1 Manganese and iron based compounds for elastogenesis and connective tissue treatment |
| 01/25/2012 | EP1685849B1 Pde 4 inhibitors for the treatment of interstitial cystitis |
| 01/25/2012 | EP1670453B1 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 01/25/2012 | EP1660458B1 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 01/25/2012 | EP1624753B1 Purinergic modulation of smell |
| 01/25/2012 | EP1590000B1 Hardenable thermally responsive compositions |
| 01/25/2012 | EP1550462B1 Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 01/25/2012 | EP1503773B9 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 01/25/2012 | EP1434597B1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 01/25/2012 | EP1343860B1 A process for preparing vegetable oil fractions rich in non-tocolic, high-melting, unsaponifiable matter |
| 01/25/2012 | EP1330456B9 N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents |
| 01/25/2012 | EP1310494B1 PPAR (delta) ACTIVATORS |
| 01/25/2012 | EP1074543B1 Aminopiperidine derivatives as integrin alpha v beta 3 antagonists |
| 01/25/2012 | CN202122698U Schistosome protecting ointment package |
| 01/25/2012 | CN1981872B Use of PUMA in tumor chemoradiotherapy sensibilization |
| 01/25/2012 | CN1965834B Enrofolxacn solution containing clustered water used for animal |
| 01/25/2012 | CN1960988B Compounds and compositions as protein kinase inhibitors |
| 01/25/2012 | CN1939316B Microsphere containing adriamycin, its usage and preparation |
| 01/25/2012 | CN1931229B Medicine for treating acute and chronic nasopharyngitis and its preparation process |
| 01/25/2012 | CN1914196B 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratiory syncytial virus replication |
| 01/25/2012 | CN1914187B Crystalline polymorphs of a CXC-chemokine receptor ligand |
| 01/25/2012 | CN1897890B Use of alginate matrices to control cell growth |
| 01/25/2012 | CN1863521B Pharmaceutical composition comprising malonamide derivative for decreasing sebum production |
| 01/25/2012 | CN1809561B Phenylacetamides and their use as glucokinase modulators |
| 01/25/2012 | CN1775219B Medicinal formulation for preventing and treating ischemic vascular disease, and its preparing method and use |
| 01/25/2012 | CN1765365B Oral soft capsule for accelerating absorption in stomach of glycoside or aglycone medicine |
| 01/25/2012 | CN1558759B 病毒聚合酶抑制剂 Viral polymerase inhibitors |
| 01/25/2012 | CN102334032A Prediction of response to platinum-based therapy |
| 01/25/2012 | CN102333869A Improved design of small-interfering rna |
| 01/25/2012 | CN102333782A Spiro azepane-oxazolidinones as kv1.3 potassium channel blockers |
| 01/25/2012 | CN102333781A Tricyclic pyrazolopyrimidine derivative |
| 01/25/2012 | CN102333779A Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| 01/25/2012 | CN102333778A Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| 01/25/2012 | CN102333777A Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| 01/25/2012 | CN102333776A Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof |
| 01/25/2012 | CN102333774A 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same |
| 01/25/2012 | CN102333773A Mineralocorticoid receptor antagonist and methods of use |
| 01/25/2012 | CN102333772A Anti-viral compounds |
| 01/25/2012 | CN102333771A Indole derivatives as crth2 receptor antagonists |
| 01/25/2012 | CN102333770A P38 map kinase inhibitors |
| 01/25/2012 | CN102333769A Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators |
| 01/25/2012 | CN102333766A Carboxamide compounds and their use as calpain inhibitors |
| 01/25/2012 | CN102333765A Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst |
| 01/25/2012 | CN102333764A Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same |
| 01/25/2012 | CN102333763A Method for manufacturing benzodiazepine derivative |
| 01/25/2012 | CN102333762A Ethanamine compounds and their use for treating depression |
| 01/25/2012 | CN102333761A Scriptaid isosteres and their use in therapy |
| 01/25/2012 | CN102333759A Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| 01/25/2012 | CN102333757A N-acyl anthranilic acid derivative or salt thereof |
| 01/25/2012 | CN102333754A Loxoprofen derivative and pharmaceutical containing same |
| 01/25/2012 | CN102333569A Amine or amino alcohols as glyt1 inhibitors |
| 01/25/2012 | CN102333568A Pharmaceutical compounds |
| 01/25/2012 | CN102333546A Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin |
| 01/25/2012 | CN102333545A Enhanced migraine treatments based on ghrelin mimetics |
| 01/25/2012 | CN102333543A Cell adhesion inhibitor and use thereof |
| 01/25/2012 | CN102333534A Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum |
| 01/25/2012 | CN102333533A Substituted quinazoline compounds |
| 01/25/2012 | CN102333532A Drug abuse deterrent, methods and compositions |
| 01/25/2012 | CN102333531A Treatment of dyskinesia related disorders |
| 01/25/2012 | CN102333530A Ceramide-analogous metabolites |